STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

NNMT inhibitor class (beyond 5-Amino-1MQ)

Also known as

NNMT inhibitors · 1MQ analogs · 5-Amino-1MQ analogs · NNMTi class · JBSNF-000088 · 6-methoxynicotinamide · JBSNF-000028 · JBSNF-000265 · MQ-scaffold NNMT inhibitors · 7-amino-1MQ · 2,3-diamino-1MQ · 1-methylquinolinium analogs · nicotinamide N-methyltransferase inhibitors · NAM-competitive NNMT inhibitors · tricyclic NNMT inhibitors (Sanofi series)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Niche talk Systemic Oral Metabolic research compounds

Systemic — whole-body NNMT block aimed at adipose/liver NAD salvage and SAM/1-MNA flux; oral small molecules dominate both papers and community talk.

What people say This card covers NNMT inhibitors beyond 5-Amino-1MQ, including JBSNF and other MQ compounds. People search them as possible alternatives, but they are not one drug and the parent dominates human anecdotes. Doses people talk about
Parent community oral band50–150 mg/day oral

5-Amino-1MQ only—not a dose for JBSNF or unidentified analog powder. Lower 5–25 mg and higher experimental charts remain below.

JBSNF-000028 mouse study50 mg/kg oral, twice daily

Multi-week DIO/diabetic-model design (~4 weeks / ~27 days), distinct from the 10 mg/kg oral PK experiment.

JBSNF-000088 mouse context~50 mg/kg oral

DIO/gavage context; the original note does not specify frequency. This is a different molecule, not a parent conversion.

Parent community amounts come first for orientation. The JBSNF rows are animal research exposures, not alternatives on a human dose ladder.

Half-life & effect duration

Half-life in the body
  • JBSNF-000028 · oral · miceAbout 2.36 hours
  • JBSNF-000028 · IV · miceAbout 1.77 hours
  • Parent 5-Amino-1MQ · oral · ratsAbout 6.9 hours
  • Parent 5-Amino-1MQ · IV · ratsAbout 3.8 hours
Felt duration people report
  • Analog-specific feelNo consistent duration reported
  • Parent-compound reportsSubtle changes, no effect, or mixed experiences during continued use
Timing context & sources
How it may feel A distinct analog “feel” is not established in the inspected material. Parent users report subtle alertness, GI/fatigue effects, changes over weeks or nothing; those experiences cannot be assigned to JBSNF compounds or the whole class.
Cycles people discuss The retained 8–12-week blocks and 2–4 or 4–6-week breaks describe parent culture. Shorter 4–6-week experiments and animal courses are separate; none defines a human cycle for an unidentified analog. Timing AM/midday splits and later-in-a-cut stack sequencing come from parent discussion. Oral, SC and IV research contexts differ; a member's animal half-life cannot set the class's daily or weekly interval. Stacks GLP-1, MOTS-c and NMN/NR stack talk mostly concerns parent 5-Amino-1MQ. Analog-specific combinations remain speculative, with no shared interaction or dosing standard. Watch for Human safety gap (class): True-analog human AE data are sparse-to-absent; most tolerability talk is parent 5-Amino-1MQ anecdotes plus short rodent “no overt tox” windows. Reviews note insufficient human validation and PK challenges for the inhibitor class.
Related
5-Amino-1MQ

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

The class has no single half-life to report.

For JBSNF-000028, mouse means were 2.36 h after oral 10 mg/kg and 1.77 h after IV 1 mg/kg. Parent 5-Amino-1MQ has different rat measurements.

Neither member's kinetics establishes another analog's human half-life, oral bioavailability or dosing interval.

  • Ruf et al. — JBSNF-000028 NNMT inhibitor study (opens in a new tab)Actual Europe PMC fullTextXML: Table 5, pharmacokinetic methods (C57BL/6 mice), DIO efficacy description, and CEREP selectivity paragraph.JBSNF-000028 only: oral 10 mg/kg and IV 1 mg/kg PK; 50 mg/kg twice-daily animal efficacy is separate. Mouse results do not give a class-wide or human schedule. MAO-A finding is a 10 µM laboratory screen, not a clinical interaction test.
  • Awosemo et al. — LC-MS/MS rat pharmacokinetics of 5-AMQ (opens in a new tab)Original abstract accessed through Europe PMC core record, PMID 34304009; final PK results paragraph.Rat plasma parent assay. Abstract gives oral/IV half-lives and oral bioavailability but not administered doses or salt form; it does not measure human capsules or SC products.

Felt duration people report

An analog-specific felt window is not established by the inspected reports.

The actual parent month-log and mixed SC thread include subtle effects, nulls and confounded co-use. They cannot supply a JBSNF or class-wide clock.

The checked analog study measures animal PK/PD, not human experience; missing analog accounts are a bounded research gap, not proof that no effects occur.

  • Experience with 5-Amino-1MQ after a month (opens in a new tab)Actual post by Remarkable_Soil_2374 (Dec. 25, 2025), Dosage/Experience/Negatives; comments by Naven71, DiscreetAcct4 and PamelaF3211.Unverified oral capsules, calorie deficit and training. OP describes 2–3-week impressions and week-3 muted affect; Naven71 reports no effect after 30 days. Other commenters use different routes/blends. No isolated single-dose duration.
  • Looking for real-world experiences and data on 5-Amino-1MQ (opens in a new tab)Actual comments by Theappache10 (500 mcg–1.5 mg SC; limited energy, no claimed fat-burning benefit), Dull_Secretary_6734 (two weeks with Reta), and Letsgobeachfun (second dose with SS-31/Tirz/Glow).Unverified products, route and dose differences, co-use and short observation. OP asks a question rather than reporting completed use. Comments do not establish chloride superiority or a human half-life.
  • Ruf et al. — JBSNF-000028 NNMT inhibitor study (opens in a new tab)Actual Europe PMC fullTextXML: Table 5, pharmacokinetic methods (C57BL/6 mice), DIO efficacy description, and CEREP selectivity paragraph.JBSNF-000028 only: oral 10 mg/kg and IV 1 mg/kg PK; 50 mg/kg twice-daily animal efficacy is separate. Mouse results do not give a class-wide or human schedule. MAO-A finding is a 10 µM laboratory screen, not a clinical interaction test.

What people say 13

  • Human recomp talk: Almost entirely parent 5-Amino-1MQ logs and clinic blogs; true JBSNF / obscure MQ-analog human diaries are rare to nonexistent in public forums. forum
  • Stack halo: When “NNMTi” appears inside GLP-1 + NAD precursor + MOTS-c stacks, credit almost always tracks the parent oral product, not a verified alternate analog. forumanecdote
  • Lean-mass narrative: Class marketing: fat down without appetite crash or lean collapse in short rodent windows; human DXA-quality isolation of any analog is missing. animalforum
  • Class fat/weight (animal): Multiple independent NNMTi chemotypes reduce body weight and white-fat mass vs vehicle in diet-induced obesity models, often without matched food-intake drop — appetite-independent recomp is the class selling point. animal
  • 5-Amino-1MQ parent (DIO mice, Neelakantan 2018): ~11-day SC NNMTi produced progressive body-weight loss; epididymal fat pad weight and adipocyte size down; popular summaries cite >7% total body weight and ~30% white-fat mass/cell-size reduction vs placebo with matched food intake. animal
  • JBSNF-000088 / 6-methoxynicotinamide (animal): Oral treatment reduced body weight, improved insulin sensitivity, normalized glucose tolerance toward lean controls in HFD-obesity models; reduced visceral WAT MNA, fed glucose, and plasma/liver triglycerides. animal
  • JBSNF-000028 (animal, Ruf 2022): Oral 50 mg/kg b.i.d. limited weight gain / reduced body weight % vs vehicle in DIO (significant from ~day 23), with comparable cumulative energy intake; also profiled in db/db and ob/ob. Insulin sensitization / glucose modulation reported. animal
  • JBSNF-000028 nuance: Glucose-tolerance improvement was also seen in NNMT knockout DIO mice — authors note metabolic benefit may partly go beyond pure NNMT inhibition. animal
  • JBSNF-000265 (animal PK/PD): Oral 50 mg/kg reduced MNAM formation ~80% within ~2 h in mouse target-engagement work (SAR-improved NAM-pocket binder). animal
  • Adipocytes (in vitro, MQ series): Membrane-permeable MQ inhibitors (especially 5-amino-1MQ) cut intracellular 1-MNA, raised NAD+ and SAM, and suppressed lipogenesis; parent 1-MQ / product 1-MNA themselves lack useful passive permeability. lab
  • Selectivity (parent scaffold series): 5-amino-1MQ-class work described high selectivity vs related SAM-dependent methyltransferases (COMT, DNMT1, PRMT3) and NAD salvage enzymes (NAMPT, SIRT1) at tested panels. trial
  • JBSNF-000028 safety screens (preclinical): Inactive on a diabetes/obesity receptor panel at 10 µM; no HepG2 cytotoxicity at 10–100 µM / 72 h in reported screens; Ames and micronucleus negative; notable MAO-A inhibition (~90% at 10 µM) flagged in Cerep panel. trial
  • Aged muscle (parent NNMTi, mice): 5-amino-1MQ SC (~10 mg/kg range, multi-week) improved grip strength vs sedentary aged controls; additive framing with exercise in 2024 Sci Rep-class reports — analog-specific muscle diaries essentially absent. animal

Doses people talk about 18

  • Critical identity rule: Parent 5-Amino-1MQ oral/inject charts do not equal JBSNF mg/kg numbers, and unlabeled gray-market “1MQ analog / NNMTi” powders have unknown assay — doses are untrustworthy without identity proof. forum
  • Parent oral common band (what most “analog” searches still land on): ~50–150 mg/day by mouth is the most repeated research-community range; 50 mg capsules are a frequent unit; ~75–100 mg/day often cited as a “usual” target after 1–2 week start at ~50 mg. forum
  • Parent oral titration talk: A copied parent chart describes ~50 mg once daily for 1–2 weeks, then ~100 mg/day; some writers claim diminishing returns / more sides above ~150 mg. This is not an instruction or an analog dose schedule. forum
  • Parent oral split: BID AM + midday splits appear in parent discussion, sometimes justified by multi-hour rodent t½ rather than weekly-peptide logic. That argument does not establish a human interval for the parent or any analog. forum
  • Parent oral conservative charts: ~5–25 mg/day oral appears in some GLP-1-adjunct stack blogs (start 5 mg → 10–25 mg); other writers call this under-dosed vs aggressive allometric HED from mice. forum
  • Parent oral high / exploratory: 100–300 mg+/day and allometric chatter near ~400–600 mg/day for “near-complete inhibition” style YouTube/HED talk — explicitly experimental, not validated human PK. forum
  • Parent injectable mcg band: Separate clinic/forum culture ~150–500 mcg/day SC — same name, totally different magnitude; never mix charts. forum
  • Route mismatch: Oral-active NAM/tricyclic leads (JBSNF series) vs SC-heavy early MQ POC for 5-amino-1MQ — do not copy parent inject math onto oral JBSNF papers or vice versa. trialforum
  • Unit chaos harm path: Rodent mg/kg → “human chart,” mg vs mcg inject labels, and “analog = same as 5-Amino-1MQ” assumptions are the main practical risks. forum
  • JBSNF-000088 potency (biochem): IC₅₀ ≈ 1.8 µM human / 2.8 µM monkey / 5 µM mouse NNMT; cellular MNA IC₅₀ ≈ 1.6 µM (U2OS) and 6.3 µM (3T3-L1) in Cayman-style datasheets. triallab
  • MQ SAR siblings (lab only): 7-amino-1MQ (IC₅₀ ~2.6 µM, high Caco-2 permeability) and 2,3-diamino-1MQ (IC₅₀ ~2.8 µM, moderate efflux) were characterization tools — no established consumer dose culture. labtrial
  • Framing: Discussed ranges are research/community or preclinical context only — not advice, not interchangeable across molecules, not approved human dosing. forumtrial
  • JBSNF-000088 (animal only): Commonly cited oral ~50 mg/kg in DIO mice (gavage); reduces visceral WAT MNA, weight, glucose, TG; improves OGTT — not a human dose. Vendor notes sometimes quote ~40% oral bioavailability context for this lead. animaltrial
  • JBSNF-000028 (animal only): Oral 50 mg/kg twice daily (b.i.d.) for multi-week DIO (~4 weeks / ~27 days designs) and diabetic models; far more potent biochemically (hNNMT IC₅₀ ~0.033 µM; cellular EC₅₀ ~2.5 µM for MNA drop). animaltrial
  • JBSNF-000028 mouse PK (not human): IV 1 mg/kg: t½ ~1.77 h, CL ~36.6 mL/min/kg, Vd ~8.69 L/kg; oral 10 mg/kg: Cmax ~452 ng/mL at Tmax 1 h, t½ ~2.36 h. BID efficacy dosing is a separate animal design, not a human schedule established by these PK measurements. animal
  • JBSNF-000265 (animal only): Oral 50 mg/kg produced ~80% MNAM reduction within ~2 h in target-engagement reports. animal
  • Aged-muscle animal dose (parent): ~10 mg/kg SC multi-week (e.g. ~8 weeks) in aged-mouse grip-strength designs. animal
  • 5-Amino-1MQ animal (not human): Neelakantan DIO: 20 mg/kg SC three times daily (~60 mg/kg/day nominal; ~34 mg/kg/day free parent in free-weight framing) for 11 days; pilot escalation ~10–150 mg/kg/day total with ~60 mg/kg/day called well tolerated in n=2. animal

How it may feel 8

  • Days 1–7 (parent-dominated): Little stimulant buzz; minority report mild GI, fatigue, or nonspecific “warmth/alertness.” Not caffeine-like. forum
  • Weeks 1–2 (parent self-logs): Scale, waist tape, photos, stool and sleep are tracked; subjective “on” is often described as weak and appetite as relatively unchanged versus GLP-1s. This does not establish a felt timeline for true analogs. forum
  • Weeks 3–4: Common first reassess window for parent; nulls often blame product identity, under-dosing relative to HED talk, or missing deficit. forum
  • Weeks 6–12: Typical oral research-block length borrowed from parent culture for any “NNMTi” experiment. forum
  • No change ~4–6 wk (parent culture): Discussion often revisits deficit, steps/NEAT, sleep, protein and COA identity—especially whether an “analog” powder is actually 5-Amino-1MQ or an unknown material. These are disputed explanations for nulls, not instructions or proof of under-dosing. forum
  • Analog gap: JBSNF-000088/028/265 and SAR MQ siblings have almost no public self-experimentation timeline lore; claiming a unique “JBSNF feel” is not supported by community volume. forum
  • Honest framing: “Feel over time” for true analogs is mostly extrapolated from parent 5-Amino-1MQ community logs plus paper endpoints — JBSNF/MQ leads are literature reagents, not mature consumer products with feel diaries. forum
  • Paper timelines (not human feel): JBSNF-000028 DIO body-weight separation ~day 23 of BID oral; 5-amino-1MQ classic obesity POC was an 11-day SC course; JBSNF-000088-style oral courses often ~4 weeks in DIO writeups. animal

Cycles people discuss 8

  • Parent-borrowed oral block: 8–12 weeks on is repeatedly described in existing “NNMTi / 5-Amino-1MQ” notes. The inspected parent reports and preclinical analog paper do not establish an analog-specific human cycle. forum
  • Off period (parent culture): ~2–4 weeks off common; some guides prefer ~4–6 weeks off for informal “reset” talk. forum
  • Short probe: 4–6 weeks before calling a null recomp result if diet/steps are controlled. forum
  • Clinic-style shorter: Some longevity writeups mention ~4–6 week parent blocks with ongoing NAD support. forum
  • Continuous use: Discussed more for parent than for obscure analogs; multi-year human safety for any NNMTi is not established. forumtrial
  • Re-runs: Next diet phase / GLP-1 plateau restarts common for parent; no analog-specific re-run lore. forum
  • Stack sequencing example (blog, not trial): One pattern describes GLP-1 titration first, then MOTS-c + NMN/NR, with NNMTi (parent) added later in a cut. This is borrowed sequencing, not a studied analog protocol or an instruction to add agents. forum
  • Rodent courses (papers, not human safety): Days–few weeks typical — e.g. 11-day SC 5-amino-1MQ POC; ~4-week oral JBSNF-000028/088-class DIO designs; multi-week aged-muscle SC courses. animal

Timing 9

  • JBSNF-000088 human PK gap: The checked sources do not supply a human estimate for this member. Community timing is borrowed from the parent or from animal 50 mg/kg oral designs; neither establishes JBSNF-000088 human kinetics. forum
  • Dosing logic in discussion: Once-daily or BID oral and multi-daily SC schedules in early mouse POCs are contrasted with weekly depot-peptide logic. A short half-life in one molecule/species does not establish a schedule for the NNMTi class. forum
  • Split-dose rationale: BID AM/midday for parent and BID designs in JBSNF-000028 efficacy papers align with multi-hour coverage, not proven human superiority of any split. animalforum
  • Visible change lag (community): Waist/scale movement, if any, tracks deficit consistency over weeks more than Cmax day. anecdote
  • Class note: Half-life and oral bioavailability are compound-specific — never treat “NNMTi class t½” as one number. trial
  • Parent rat PK (widely cited LC-MS/MS): Oral terminal t½ ~6.9 h; IV ~3.8 h; oral F ≈ 38%; substantial oral plasma exposure (e.g. mean Cmax ~2252 ng/mL in that rat design). animal
  • JBSNF-000028 mouse PK: Oral t½ ~2.36 h (10 mg/kg); IV t½ ~1.77 h (1 mg/kg); rapid absorption (Tmax ~1 h) and concurrent plasma MNA drop = target engagement. animal
  • Downstream lag: MNA/tissue metabolic endpoints and body-comp change track repeated dosing over days–weeks, not one acute plasma peak. animal
  • MNA as PD marker: Class papers use plasma/adipose/liver MNA (1-MNA) drop as target engagement — useful lab concept, not a consumer home assay. trial

More on what it is 6

  • Why people search “analogs”: After 5-Amino-1MQ forum/clinic hype, researchers and vendors hunt “next” or alternate NNMTis — potency, oral PK, or marketing novelty — even though almost all human anecdote volume still rides the parent molecule. forum
  • Not one drug: Shared target ≠ same dose, half-life, oral F, selectivity, or safety. Parent oral charts do not transfer to JBSNF numbers or unlabeled “1MQ analog” powders. forumtrial
  • Not: Not GLP-1s, not NMN/NR (those are substrates/precursors), not the enzyme NNMT itself (vendors sometimes mislabel), not approved weight-loss medicines. trialforum
  • What it is: The broader research class of small-molecule nicotinamide N-methyltransferase (NNMT) inhibitors beyond the consumer-famous parent 5-Amino-1MQ — includes NAM analogs (e.g. JBSNF-000088 / 6-methoxynicotinamide), later Sanofi tricyclics (JBSNF-000028, JBSNF-000265), and other methylquinolinium (MQ) positional analogs from the UTMB SAR series (7-amino-1MQ, 2,3-diamino-1MQ, poorly permeable 1-MQ / diMQ / tetraMQ scaffolds). trial
  • Shared mechanism story: NNMT methylates nicotinamide (NAM) using SAM → makes 1-methylnicotinamide (1-MNA / MNA) and consumes methyl groups. Blocking NNMT is framed as raising local NAD+ precursor availability + SAM (methylation potential) and shifting adipocytes away from lipogenesis / storage phenotype. labanimal
  • Evidence honesty: Dense preclinical package (cells + DIO/db/db/ob/ob rodents for several named leads); as of mid-2026 reviews, published human efficacy RCTs for NNMT inhibitors as weight-loss drugs are not established — “clinical trials focusing on NNMT have not been documented” in broad 2024 class reviews. trial

Stacks 9

  • GLP-1 / dual / triple agonists: Semaglutide, tirzepatide, retatrutide — NNMTi framed as non-anorectic fat-metabolism / visceral adjunct once a deficit exists; late-plateau midsection talk. forum
  • NAD precursors: NMN or NR (community stack blogs often ~250–500 mg/day) under “NNMT frees NAD salvage / stop the nicotinamide bleed” logic; sometimes sequenced before the NNMTi layer. forum
  • MOTS-c: Very common “mito spend + NNMT block” pair with parent; AMPK/mito narrative + NAD-pool protection story. forum
  • Full metabolic mega-stack (blog pattern, not trial): GLP-1 or retatrutide + MOTS-c + NMN/NR + parent 5-Amino-1MQ — attribution impossible. forum
  • GH-axis / lipolytic neighbors: Tesamorelin, AOD-9604, Frag 176-191, ipamorelin/CJC-class in multi-agent cuts. forum
  • Other recomp RCs: SLU-PP-332 (exercise-mimetic; different target), BAM15 (mitochondrial uncoupler talk), cardarine-style — high confounders. forumanecdote
  • Basics still credited: Best reports credit measured deficit, steps/NEAT, high protein, and progressive lifting when “results looked good.” forum
  • Analog-specific stacks: Essentially none documented — people stack the parent product and only theorize about next-gen NNMTis. forum
  • Stack caution: No systematic interaction trials of any NNMTi with GLP-1s, NAD precursors, or multi-peptide piles. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 14

  • Human safety gap (class): True-analog human AE data are sparse-to-absent; most tolerability talk is parent 5-Amino-1MQ anecdotes plus short rodent “no overt tox” windows. Reviews note insufficient human validation and PK challenges for the inhibitor class. forumtrial
  • Parent-dominated subjective sides: Mild GI (nausea, loose stool), headache, early fatigue, occasional sleep disruption with evening dosing — stacks blur causality. forum
  • Injection local (if any SC parent product): Sting, itch, redness; IM is nonstandard and called out as label error in community QC posts. forum
  • Methylation theory risk: Chronic systemic NNMT block could theoretically perturb SAM/SAH one-carbon balance and epigenetic methylation programs outside adipose — discussed as theoretical, not a proven clinical table of harms. forumtrial
  • Cancer biology complexity: NNMT is overexpressed in multiple cancers and is a biomarker/promoter in oncology literature; net long-term effect of systemic NNMT inhibition on cancer risk in humans is unknown. Active malignancy is a common community caution flag. trialforum
  • Mislabel / gray-market risk: Wrong molecule, enzyme-vs-inhibitor label errors, unknown “1MQ analog” powders, weak COAs, contamination — higher for obscure analogs than for well-known parent SKUs. forum
  • Unit chaos: mcg/mg mix-ups and rodent mg/kg → human charts are a documented harm path across the parent ecosystem and worse when identity is unclear. forum
  • Interactions: No solid clinical interaction data with common metabolic meds, multi-peptide stacks, or NAD megadoses. forum
  • 1-MNA duality: The NNMT product 1-MNA has its own reported bioactivities (including protective narratives in some CV contexts); blocking production is not a free lunch conceptually. trial
  • JBSNF-000028 off-target note: Preclinical Cerep panel showed strong MAO-A inhibition at 10 µM — molecule-specific, not proven clinical MAOI-class interaction, but a reason not to assume “all NNMTis are clean.” trial
  • Vs approved agents: Semaglutide/tirzepatide have large Phase 3 weight-loss packages; NNMTi class members do not — mechanism interest ≠ clinical equivalence. trial
  • Pregnancy / lactation / long-term: Not characterized; research-only framing. forum
  • Not “rodent well-tolerated = human safe”: Short DIO courses and clean cell panels do not replace controlled AE capture, labs, or multi-year follow-up. animaltrial
  • Research-only: Investigational reagents / research chemicals — not approved weight-loss medicines. trial

Updated: 2026-08-12

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →